Skin Irritation Clinical Trial
Official title:
Daily Advance Cetaphil Moisturizing Lotion: Human Repeat Insult Patch Test
NCT number | NCT01892423 |
Other study ID # | GLI.04SPR.US10044 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2006 |
Verified date | June 2013 |
Source | Galderma R&D |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Human repeat insult patch test to assess the potential for Cetaphil Moisturizing Lotion Daily Advance to induce sensitization to the skin
Status | Completed |
Enrollment | 146 |
Est. completion date | |
Est. primary completion date | September 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age 18-65 years - Good health - willingness to cooperate and participate - willingness to avoid topical products at test sites - willingness to avoid direct sun exposure to test sites Exclusion Criteria: - Individuals with active psoriasis or eczema - individuals with sunburn, acne, abrasions, scar tissue, or tattoos on test sites, or disease of skin that might interfere - individuals who have had a mastectomy with axillary nodes were removed - individuals receiving anticancer, immunosuppressive treatments or medications, or radiation - pregnant, nursing, or planned to become pregnant - use of topical steroids or drugs at test sites - active or untreated skin cancer - active hepatitis - current routine or frequent use of high doses of anti-inflammatory drugs - individuals who have had les than two week rest period since completion of previous patch testing on upper back or upper arms - individuals with uncontrolled metabolic diseases |
Country | Name | City | State |
---|---|---|---|
United States | Thomas J Stephens and Associates Inc | Carrollton | Texas |
Lead Sponsor | Collaborator |
---|---|
Galderma R&D |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Irritation responses | all patients will be assessed at 14 visits for redness (erythema), spreading, weeping, papules, vesicles, and bullae at application site | average of 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01806831 -
Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment
|
N/A | |
Completed |
NCT02297841 -
Repeated Insult Patch Test of Personal Lubricants
|
N/A | |
Completed |
NCT02968446 -
Effect of Vitamin D After Application With Valchlor
|
Early Phase 1 | |
Completed |
NCT03397862 -
A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System
|
Phase 1 | |
Unknown status |
NCT01821274 -
A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design
|
Phase 1 | |
Completed |
NCT01892657 -
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
|
Phase 4 | |
Withdrawn |
NCT02400320 -
Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
|
Phase 4 | |
Not yet recruiting |
NCT02645110 -
Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations
|
N/A | |
Completed |
NCT01887808 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
|
N/A | |
Completed |
NCT01892410 -
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
|
N/A | |
Completed |
NCT01887860 -
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
|
N/A | |
Completed |
NCT01888887 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
|
N/A |